ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of February 3, 2023, ACRS stock price declined to $14.05 with 1,790,643 million shares trading.

ACRS has a beta of 0.46, meaning it tends to be less sensitive to market movements. ACRS has a correlation of 0.02 to the broad based SPY ETF.

ACRS has a market cap of $936.90 million. This is considered a Small Cap stock.

Last quarter Aclaris Therapeutics reported $19 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.10.

In the last 3 years, ACRS stock traded as high as $30.38 and as low as $.70.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

ACRS has outperformed the market in the last year with a return of +29.7%, while the SPY ETF lost -6.3%. However, in the most recent history, ACRS shares have underperformed the stock market with its stock returning -7.7% in the last 3 month period and -15.6% for the last 2 week period, while SPY has returned +11.6% and +4.2%, respectively.

ACRS support price is $13.66 and resistance is $15.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS stock will trade within this expected range on the day.